<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> is a key event of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) progression </plain></SENT>
<SENT sid="1" pm="."><plain>Mesothelin is expressed in various types of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumor</z:e> and associated with an unfavorable prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>The full-length mesothelin (Full-ERC) is cleaved by protease into membrane-bound C-ERC/mesothelin and N-ERC/mesothelin which is secreted into the blood </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this study was to examine the biological role of mesothelin in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> by clinicopathological analysis and in vitro lymphatic invasion assay </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Ninety-one cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> specimens were immunohistochemically examined and the localization of mesothelin in <z:chebi fb="2" ids="8069">luminal</z:chebi> membrane and/or cytoplasm was also evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>Lymphatic invasion assay was also performed using the human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell line, WiDr, which was transfected with Full-, N- and C-ERC/mesothelin expression plasmids (Full-WiDr, N-WiDr and C-WiDr) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Immunohistochemically, "<z:chebi fb="2" ids="8069">luminal</z:chebi> membrane positive" of mesothelin was identified in 37.4 %, and correlated with lymphatic permeation and lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, but not with patients' prognosis </plain></SENT>
<SENT sid="7" pm="."><plain>Interestingly, among the patients with lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (N = 38), "<z:chebi fb="2" ids="8069">luminal</z:chebi> membrane positive" of mesothelin significantly correlated with unfavorable patients' outcome </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, lymphatic invasion assay revealed that Full-WiDr and C-WiDr more significantly invaded human lymphatic endothelial cells than the Mock-WiDr (P &lt; 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The <z:chebi fb="2" ids="8069">luminal</z:chebi> membrane expression of mesothelin was associated with unfavorable prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Moreover, this is the first report to prove the biological function of C-ERC/mesothelin associated with lymphatic invasion of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in vitro </plain></SENT>
</text></document>